OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) and Earth Life Sciences Inc (OTCMKTS:CLTS) have been quite vigilant in developing top solutions that will be to the best interests of patients in the U.S and the world at large. They have today in collaboration with the National Center for Complementary and Integrative Health (NCCIH) engaged in non-clinical studies which are expected to help towards the achievement of a clinical development plan for cystine as some form of smoking cessation treatment.
Achieve is giving out Cytisine to the NIH with the purpose of supporting a series of non-clinical studies which are supposed to act as a form of support for their Investigational New Drug (IND) application. The move is meant assist in the push to get the U.S. Food and Drug Administration (FDA) to approve their new drug.
2015 is the year the collaboration kick-started and reliable sources say that in the second-quarter of 2017 the results of the initial study will already be out. The smoking related illnesses have destroyed so many lives and at the same time taken lots of lives. Through conferences, workshops and public rallies, a lot has been said to advice the general public on the dangers of smoking. However, not much seems to have changed yet Biotech Stock News show related companies making huge progress on financial gain.
Some of the top medical practitioners have come forward to assert that Cystine is indeed a drug of great public health importance as it has been proved by the series tests that have been done before. There is great hope that the collaborations in place will as a matter of fact do much towards providing the public with sufficient smoking cessation aids. That will be a great step forward in the quest to try and minimize the number of lives lost each year as a result of the smoking habit.
According to the U.S. Surgeon General’s 2014 report the health consequences attributed to the smoking habit has affected 16 million Americans and at the same time every year America mourns 480,000 deaths. The wide range of complications associated with smoking are pretty costly in terms of treatment s reports indicate that the annual costs of direct medical care amount to $130 billion.
Chairman and Chief Executive Officer of Achieve , Rick Stewart showed his gratitude over the move by NIH which has seen Achieve move ahead with the update for non-clinical package for Cytisine. Phase 1 studies are set to commence later on this year whereas the Phase 3 trial may proceed in the first half of 2018.Biotech Stocks 2017 continue their steady competition while on the other hand the world continues to mourn lives.